1h Free Analyst Time
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma - Drugs In Development, 2022, provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 3, 4, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 2 and 2 molecules, respectively.
Recurrent Malignant Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Recurrent Malignant Glioma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Recurrent Malignant Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Recurrent Malignant Glioma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Recurrent Malignant Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Report Coverage
- Recurrent Malignant Glioma - Overview
- Recurrent Malignant Glioma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Recurrent Malignant Glioma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
- Candel Therapeutics Inc
- Hebei Senlang Biotechnology Co Ltd
- Immunomic Therapeutics Inc
- Moleculin Biotech Inc
- Oblato Inc
- PharmAbcine Inc
- Smerud Medical Research International AS
- Stella Pharmaceuticals Pvt Ltd
- Sumitomo Pharma Co Ltd
- Recurrent Malignant Glioma - Drug Profiles
- 2141 V-11 - Drug Profile
- Product Description
- Mechanism Of Action
- 2X-111 - Drug Profile
- Product Description
- Mechanism Of Action
- bevacizumab biosimilar - Drug Profile
- Product Description
- Mechanism Of Action
- borofalan - Drug Profile
- Product Description
- Mechanism Of Action
- CAN-3110 - Drug Profile
- Product Description
- Mechanism Of Action
- disufenton sodium - Drug Profile
- Product Description
- Mechanism Of Action
- DSP-0390 - Drug Profile
- Product Description
- Mechanism Of Action
- Gene Therapy to Target EphA2 for Recurrent Malignant Glioma - Drug Profile
- Product Description
- Mechanism Of Action
- ITI-1000 - Drug Profile
- Product Description
- Mechanism Of Action
- Memory Enriched T Cells - Drug Profile
- Product Description
- Mechanism Of Action
- SENL-006 - Drug Profile
- Product Description
- Mechanism Of Action
- Vaccine to Target URLC10, DEPDC1, FOXM1, KIF20A VEGFR1 and VEGFR2 for Malignant Glioma - Drug Profile
- Product Description
- Mechanism Of Action
- WP-1066 - Drug Profile
- Product Description
- Mechanism Of Action
- Recurrent Malignant Glioma - Dormant Projects
- Recurrent Malignant Glioma - Discontinued Products
- Recurrent Malignant Glioma - Product Development Milestones
- Featured News & Press Releases
- Apr 22, 2022: Moleculin obtains FDA clearance for Phase I glioma treatment trial
- Dec 06, 2017: Moleculin's WP1066 Drug receives $2 million Private Grant
- Dec 05, 2017: Moleculin's WP1066 Drug gets FDA Brain Tumor IND Clearance
- Apr 21, 2017: Japan's Ministry of Health, Labour and Welfare Announces SAKIGAKE Designation For Stella Pharma's Cancer Drug
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development for Recurrent Malignant Glioma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Products under Development by Companies, 2022
- Products under Development by Universities/Institutes, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Recurrent Malignant Glioma - Pipeline by Candel Therapeutics Inc, 2022
- Recurrent Malignant Glioma - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2022
- Recurrent Malignant Glioma - Pipeline by Immunomic Therapeutics Inc, 2022
- Recurrent Malignant Glioma - Pipeline by Moleculin Biotech Inc, 2022
- Recurrent Malignant Glioma - Pipeline by Oblato Inc, 2022
- Recurrent Malignant Glioma - Pipeline by PharmAbcine Inc, 2022
- Recurrent Malignant Glioma - Pipeline by Smerud Medical Research International AS, 2022
- Recurrent Malignant Glioma - Pipeline by Stella Pharmaceuticals Pvt Ltd, 2022
- Recurrent Malignant Glioma - Pipeline by Sumitomo Pharma Co Ltd, 2022
- Recurrent Malignant Glioma - Dormant Projects, 2022
- Recurrent Malignant Glioma - Discontinued Products, 2022
- Number of Products under Development for Recurrent Malignant Glioma, 2022
- Number of Products under Development by Companies, 2022
- Number of Products under Development by Universities/Institutes, 2022
- Number of Products by Top 10 Targets, 2022
- Number of Products by Stage and Top 10 Targets, 2022
- Number of Products by Top 10 Mechanism of Actions, 2022
- Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Number of Products by Top 10 Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Top 10 Molecule Types, 2022
- Number of Products by Stage and Top 10 Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Candel Therapeutics Inc
- Hebei Senlang Biotechnology Co Ltd
- Immunomic Therapeutics Inc
- Moleculin Biotech Inc
- Oblato Inc
- PharmAbcine Inc
- Smerud Medical Research International AS
- Stella Pharmaceuticals Pvt Ltd
- Sumitomo Pharma Co Ltd
